Existing data for androgen receptor (AR) antagonists are encouraging and anticipated future results could soon show a benefit for these agents in large populations of patients with breast cancer.
Radiologists have been challenged by the ever-changing recommendations of when breast cancer screening should begin and the frequency of screening, says Sarah M. Friedewald, MD. The controversy surrounding screening recommendations can be a distraction to the implementation of new technologies, such as tomosynthesis.
Kimberly J. Van Zee, MS, MD, FACS, presented her findings on the benefits of nomogram during a panel on “Breast Pathology for the Non-Pathologist” at the 18th annual Lynn Sage Breast Cancer Symposium in Chicago.
The selection process for determining which procedure to utilize for an image-directed core breast biopsy often remains a mystery to those outside of the pathology and radiology world.
William J. Gradishar, MD, discusses combining and sequencing novel targeted therapies.